Deferiprone

Drug Profile

Deferiprone

Alternative Names: CGP 37391; CMX 001 - CorMedix; CP 020; CP 20; CRMD-001; Ferriprox; Ferriprox Oral Solution; Kelfer; L1

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Royal Free and University College Medical School
  • Developer Apotex; Centre Hospitalier Univeristaire De Lille; CorMedix
  • Class Antianaemics; Antineoplastics; Antirheumatics; Pyridones; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Iron overload
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Iron overload
  • Phase III Pantothenate kinase-associated neurodegeneration
  • Phase II Amyotrophic lateral sclerosis; Parkinson's disease
  • Phase I HIV infections
  • No development reported Friedreich's ataxia
  • Discontinued Kidney disorders

Most Recent Events

  • 11 Jan 2017 ApoPharma completes a phase III trial in Pantothenate Kinase Associated Neurodegeneration in Italy, Germany, USA and United Kingdom (PO) (NCT01741532)
  • 01 Dec 2016 ApoPharma completes the phase II trial in Amyotrophic lateral sclerosis in France (PO) (NCT02164253)
  • 05 Aug 2016 Phase-II clinical trials in Parkinson's disease (Early-stage disease, Treatment-experienced) in USA (PO, Controlled-release) (NCT02728843)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top